成人遗传性肾病:病理学家的视角
单基因病占成人慢性肾脏病(CKD)的10%-20%。2024 KDIGO CKD指南强调对不明原因CKD考虑基因检测。本综述为病理学家和肾内科医生概述遗传性肾病的组织学模式,并提供肾活检报告与临床病理讨论的实用框架。
要点
- 单基因病占成人CKD的10%-20%,应重视基因检测。
- 病理学家在常规肾活检中可首先提示遗传性肾病。
- 2024 KDIGO指南建议不明原因CKD时考虑基因检测。
核心结论
- 识别遗传性肾病可提供明确诊断并指导管理,包括疾病特异性治疗、肾外表现筛查、早期肾保护、避免无效治疗、了解疾病进程及移植后复发风险、生殖咨询。
- 病理学家在识别潜在遗传性肾病病例中起重要作用,组织学可强化怀疑或成为首个证据。
研究设计与样本
- 综述,检索范围未在摘要中明确报告。
主要发现
- 单基因病占成人CKD的10%-20%。
- 遗传性肾病可能因医生或病理学家不熟悉、缺乏明确家族史、基因型-表型异质性及/或不典型表现而被忽视。
- 病理学家参与临床病理讨论会(CPC),讨论适合基因检测的患者证据。
关键数值与推荐
- 2024 KDIGO CKD指南强调考虑基因检测,尤其在不明确CKD(CKDx)且组织学评估未确定精确病因时。
临床怎么用
- 病理学家在常规肾活检评估中应识别潜在遗传性肾病病例。
- 病理学家应参与CPC讨论,提供证据以识别适合基因检测的患者。
- 综述提供肾活检报告、接收报告及参与CPC讨论的实用框架。
局限性
- 摘要未报告综述的检索范围及局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monogenic diseases account for 10%-20% of chronic kidney disease (CKD) in adults. Their importance is increasingly appreciated in general nephrology, facilitated by more widespread access to genomic testing and expanding gene panels. The 2024 KDIGO clinical practice guideline for evaluation and management of CKD emphasizes the importance of considering genetic testing, particularly in the context of unexplained CKD (CKDx) when histological evaluation does not identify a precise aetiology. Identifying a genetic cause provides a definitive diagnosis and shapes patient management including access to disease-specific therapies, screening for extra-renal manifestations, early initiation of renoprotective measures, avoiding ineffective and potentially harmful treatments, a better understanding of the likely disease course including risk of recurrence following transplantation, and reproductive counselling. Despite this, genetic kidney disease may be overlooked due to lack of physician or pathologist familiarity, lack of clear family history, genotype-phenotype heterogeneity, and/or atypical presentations. The pathologist has an important role in identifying potential cases of genetic kidney disease as part of routine kidney biopsy assessment. Histology can either strengthen the case for a suspected genetic disease, or-not infrequently-be the first evidence of a potential underlying genetic cause. The pathologist participates in the clinicopathological correlation (CPC) meeting discussing evidence to identify patients in whom genetic testing would be appropriate. This review provides pathologists and nephrologists with an overview of the different histological patterns associated with genetic kidney disease, and outlines a practical framework for reporting kidney biopsies, receiving the reports, and/or participating in CPC discussions.
引用
- Paterson AL, Chan MMY, Roufosse C, et al. Genetic kidney disease in adults-the pathologists' perspective. Nephrol Dial Transplant. 2026. PMID: 41848274. doi:10.1093/ndt/gfag047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。